1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Inner Mongolia Furui Medical Science Co., Ltd.

Inner Mongolia Furui Medical Science Co., Ltd.

300049.SZ
Inner Mongolia Furui Medical Science Co., Ltd.CN flagShenzhen Stock Exchange
43.93
CNY
-1.79
- -
11.60BMarket Cap
Inner Mongolia Furui Medical Science Co., Ltd.
300049.SZ
(Shenzhen Stock Exchange)

Recent

price

43.93

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.85
1.21
1.64
2.13
5.18
2.31
3.14
3.1
3.18
3.25
3.15
3.46
3.83
4.39
5.12
6.01
5.45
Revenue per Share
0.19
0.21
0.16
0.02
0.7
0.35
0.46
0.23
0.13
0.17
0.24
0.37
0.37
0.39
0.43
0.58
0.35
Basic EPS, GAAP
0.04
0.14
0.25
-0.85
-0.26
0.12
-0.25
0.35
-0.06
0.74
0.35
0.55
0.38
0.44
0.01
0.61
-0.93
Free Cash Flow per Basic Share
0.1
0.07
0.16
0.01
0.03
0.11
0.11
0.12
0.11
0.01
0.01
0.01
0.27
0.2
0.01
0.01
0.01
Dividend per Share
0.75
0.93
0.93
0.97
2.63
1.98
2.3
2.4
2.37
2.69
2.92
3.24
3.53
3.52
3.93
4.44
4.18
Book Value per Share
2.75
2.2
2.2
2.27
5.13
5.18
5.69
5.45
3.81
3.81
4.09
4.82
4.84
4.83
5.18
6.43
5.58
Tangible Book Value per Share
247
249
249
245
125
262
263
266
272
256
256
260
263
263
263
266
260
Basic Weighted Avg Shares
210
302
408
523
646
604
827
823
867
832
808
898
1,009
1,154
1,349
1,595
1,420
Sales/Revenue/Turnover
27.92
22.94
12.82
3.96
19.63
19.69
21.28
18.79
15.59
16.52
18.08
19.67
18.37
21
22.89
25.03
21.73
Operating Margin (%)
8
10
11
16
41
22
35
46
44
51
69
67
72
81
91
101
- -
Depreciation Expense
47
52
41
5
87
92
121
61
35
43
62
95
98
102
113
154
90
Net Income, GAAP
24.21
22.59
24.27
88.2
30.39
18.44
20.74
47.17
61.11
20.94
20.81
21.73
24.12
24.76
27.6
26.28
31.88
Effective Tax Rate (%)
22.28
17.36
10.09
0.94
13.51
15.17
14.64
7.42
4.08
5.22
7.67
10.63
9.7
8.8
8.4
9.66
6.33
Profit Margin (%)
595
419
420
310
414
1,085
1,025
1,018
645
702
743
870
994
956
1,154
1,062
1,191
Working Capital
1
8
9
6
- -
- -
- -
10
8
69
55
54
42
45
55
69
55
LT Debt
687
703
734
749
915
1,651
1,825
1,916
1,514
1,552
1,616
1,806
1,826
1,847
2,128
2,472
2,243
Total Equity
9.35
7.04
5.02
0.3
9.45
7
7.57
4.16
2.93
6.63
6.73
7.48
7.3
9.57
10.85
12.15
9.71
Return on Invested Capital (%)
23.29
20
14.77
2.4
21.59
12.72
9.76
4.88
2.69
-1.13
3.31
3.76
4.13
2.09
2.35
3.12
1.32
Return on Capital (%)
30.53
25.25
17.78
2.09
30.92
21.65
21.52
9.82
5.51
6.5
8.61
12.01
11.07
10.96
11.55
13.91
8.61
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
21
22
23
LT Borrowings
- -
- -
- -
LT Finance Leases
55
50
55
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
266
266
266
Market Capitalization
8,297
8,312
8,443

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,524
1,521
1,563
Cash, Cash Equivalents & STI
724
726
716
Accounts Receivable, Net
526
510
559
Inventories
141
141
153
Total Current Liabilities
370
333
373
Payables & Accruals
- -
- -
- -
ST Debt
21
22
23
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.66%
9.08%
16.15%
Free Cash Flow
446.29%
1,300.31%
6,555.08%
Net Income, GAAP
11.37%
21.61%
36.02%
Sales/Revenue/Turnover
10.79%
14.62%
18.26%
Total Cash Common Dividend
334.45%
680.28%
3.87%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
323
320
337
369
1,349
2025
330
383
494
- -
1,595
2026
360
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
- -
- -
- -
0.43
2025
0.11
- -
- -
- -
0.58
2026
0.12
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
Rhythm Pharmaceuticals, Inc. (RYTM)
NeonMind Biosciences Inc. (NMDBF)
ONE Bio Corp. (ONBI)
PharmaTher Holdings Ltd. (PHRM.CN)
Stemcell Holdings, Inc. (STMM)
UCB S.A. (UCBJY)
Business
Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) engages in the research, development, production, and sale of pharmaceuticals, diagnostic equipment, and medical services focused on liver disease prevention, diagnosis, and treatment in China and internationally; its core products and services include Compound Turtle and Soft Liver Tablets for hepatology treatment, the FibroScan series of liver fibrosis diagnostic instruments, digital health management platforms, prescription drugs, and health management center services targeting chronic liver conditions such as fibrosis, hepatitis, and fatty liver disease. The company operates through two primary segments, pharmaceutical production and sales alongside diagnostic equipment research, development, production, and sales, with subsidiaries and operations extending to France, the United States, Germany, Spain, the United Kingdom, Italy, Singapore, Hong Kong, and other regions; founded in 1998 and headquartered in Beijing, China, it lists on the Shenzhen Stock Exchange GEM and maintains a workforce of approximately 867 employees serving hospitals, clinics, and patients globally. In recent developments, the company pursues strategic expansion through an equity acquisition framework agreement to acquire a 96.20% stake in Chengdu Furuihui Hospital Management Co., enhancing its medical services capabilities, while continuing partnerships with healthcare institutions and emphasizing digital transformation and international compliance certifications like ISO 13485 and CE marking amid steady revenue growth from equipment and pharmaceutical divisions.